Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data
Background: The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in elderly patients with HF with reduced ejection fraction (HFrEF). The purpose of our study is to analyze the effect of SGLT2 inhibitors (SGLT2i)...
| Autores: | , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Recursos: | Universidad Autónoma de Madrid |
| Repositorio: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.uam.es:10486/754040 |
| Acesso em linha: | https://hdl.handle.net/10486/754040 https://dx.doi.org/10.3390/biomedicines12071507 |
| Access Level: | acceso abierto |
| Palavra-chave: | HFrEF elderly SGLT2i propensity score Medicina |
| id |
ES_d2e2fca9356b5bd1317ea8bacd0a81ac |
|---|---|
| oai_identifier_str |
oai:repositorio.uam.es:10486/754040 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life DataBalaguer, JorgeCortés García, MarcelinoRodríguez López, CarlosRomero Otero, José MaríaEsteban Chapel, Jose AntonioBollas Becerra, Antonio JoséNieto Roca, LuisTaibo Urquía, MikelPello Lázaro, Ana MaríaTuñón Fernández, José LuisHFrEFelderlySGLT2ipropensity scoreMedicinaBackground: The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in elderly patients with HF with reduced ejection fraction (HFrEF). The purpose of our study is to analyze the effect of SGLT2 inhibitors (SGLT2i) in this subgroup of patients. (2) Methods: A single-center, real-world observational study was performed. We consecutively enrolled all patients aged ≥ 75 years diagnosed with HFrEF and for treatment with SGLT2i, and considered the theoretical indications. (3) Results: A total of 364 patients were recruited, with a mean age of 84.1 years. At inclusion, the mean LVEF was 29.8%. Median follow-up was 33 months, and there were 122 deaths. A total of 55 patients were under SGLT2i treatment. A multivariate Cox logistic regression test for all-cause mortality was performed, and only SGLT2i (HR 0.39 [0.19–0.82]) and glomerular filtration rate (HR 0.98 [0.98–0.99]) proved to be protective factors. In parallel, we conducted a propensity-score-matched analysis, where a significant reduction in all-cause mortality was associated with the use of SGLT2i treatment (HR 0.39, [0.16–0.97]). (4) Conclusions: Treatment with SGLT2i in elderly patients with HFrEF was associated with a lower rate of all-cause mortality. Our data show that SGLT2i therapy could improve prognosis in the elderly with HFrEF in a real-world studyThis work was supported by grants from Instituto de Salud Carlos III (ISCIII) (PI20/00923; PI24/00978), ISCIII-FEDER (FJD biobank: RD09/0076/00101), and Spanish Society of Cardiology (SEC/FEC-INV-CLI 23/13)MDPIFacultad de MedicinaDepartamento de MedicinaGobierno de EspañaInstituto de Salud Carlos III20242024-07-07research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10486/754040https://dx.doi.org/10.3390/biomedicines1207150739062080reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/7540402026-06-23T12:46:27Z |
| dc.title.none.fl_str_mv |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| title |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| spellingShingle |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data Balaguer, Jorge HFrEF elderly SGLT2i propensity score Medicina |
| title_short |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| title_full |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| title_fullStr |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| title_full_unstemmed |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| title_sort |
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data |
| dc.creator.none.fl_str_mv |
Balaguer, Jorge Cortés García, Marcelino Rodríguez López, Carlos Romero Otero, José María Esteban Chapel, Jose Antonio Bollas Becerra, Antonio José Nieto Roca, Luis Taibo Urquía, Mikel Pello Lázaro, Ana María Tuñón Fernández, José Luis |
| author |
Balaguer, Jorge |
| author_facet |
Balaguer, Jorge Cortés García, Marcelino Rodríguez López, Carlos Romero Otero, José María Esteban Chapel, Jose Antonio Bollas Becerra, Antonio José Nieto Roca, Luis Taibo Urquía, Mikel Pello Lázaro, Ana María Tuñón Fernández, José Luis |
| author_role |
author |
| author2 |
Cortés García, Marcelino Rodríguez López, Carlos Romero Otero, José María Esteban Chapel, Jose Antonio Bollas Becerra, Antonio José Nieto Roca, Luis Taibo Urquía, Mikel Pello Lázaro, Ana María Tuñón Fernández, José Luis |
| author2_role |
author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Facultad de Medicina Departamento de Medicina Gobierno de España Instituto de Salud Carlos III |
| dc.subject.none.fl_str_mv |
HFrEF elderly SGLT2i propensity score Medicina |
| topic |
HFrEF elderly SGLT2i propensity score Medicina |
| description |
Background: The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in elderly patients with HF with reduced ejection fraction (HFrEF). The purpose of our study is to analyze the effect of SGLT2 inhibitors (SGLT2i) in this subgroup of patients. (2) Methods: A single-center, real-world observational study was performed. We consecutively enrolled all patients aged ≥ 75 years diagnosed with HFrEF and for treatment with SGLT2i, and considered the theoretical indications. (3) Results: A total of 364 patients were recruited, with a mean age of 84.1 years. At inclusion, the mean LVEF was 29.8%. Median follow-up was 33 months, and there were 122 deaths. A total of 55 patients were under SGLT2i treatment. A multivariate Cox logistic regression test for all-cause mortality was performed, and only SGLT2i (HR 0.39 [0.19–0.82]) and glomerular filtration rate (HR 0.98 [0.98–0.99]) proved to be protective factors. In parallel, we conducted a propensity-score-matched analysis, where a significant reduction in all-cause mortality was associated with the use of SGLT2i treatment (HR 0.39, [0.16–0.97]). (4) Conclusions: Treatment with SGLT2i in elderly patients with HFrEF was associated with a lower rate of all-cause mortality. Our data show that SGLT2i therapy could improve prognosis in the elderly with HFrEF in a real-world study |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2024-07-07 |
| dc.type.none.fl_str_mv |
research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10486/754040 https://dx.doi.org/10.3390/biomedicines12071507 39062080 |
| url |
https://hdl.handle.net/10486/754040 https://dx.doi.org/10.3390/biomedicines12071507 |
| identifier_str_mv |
39062080 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
reponame:Biblos-e Archivo. Repositorio Institucional de la UAM instname:Universidad Autónoma de Madrid |
| instname_str |
Universidad Autónoma de Madrid |
| reponame_str |
Biblos-e Archivo. Repositorio Institucional de la UAM |
| collection |
Biblos-e Archivo. Repositorio Institucional de la UAM |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869420412331360256 |
| score |
15,812429 |